2026 ACCP/UCSF Digital Health Webinar

Live Session: Wednesday, April 29^nd, 2026, from 1:00 to 2:30 PM ET

On Demand: April 29^th, 2026 to April 29^th, 2029

Why is this webinar important to your practice? 

Learners who complete this activity will have strengthened knowledge of emerging digital health technologies and their application in clinical care and research. This activity reviews the convergence of extended reality (XR), artificial intelligence (AI), biosensing and digital twin technologies to enable more objective assessment, personalized interventions and improved patient outcomes. Content covers digital therapeutics, including regulatory pathways and reimbursement considerations, with emphasis on AI-driven, adaptive models and key challenges such as data variability, subjectivity of health outcomes and algorithmic fairness. This activity is designed to increase knowledge of digital health technologies and their potential to enhance clinical decision-making, patient monitoring and precision medicine approaches.

Target Audience:

Interprofessional team of Physicians, Pharmacists, PhDs and other health care professionals interested in the application of digital health technologies in patient care.

Learning Objectives

After completing this activity, the learner will be able to:

2026 ACCP Virtual Journal Club Webinar: Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment

Live Session: Wednesday, April 22^nd, 2026, from 12:00 to 1:00 PM ET

On Demand: April 22^nd, 2026 to April 22^nd, 2029

Why is this webinar important to your practice? 

Learners that complete this webinar will have enhanced knowledge of the impact of hepatic impairment on drug metabolism and pharmacokinetics. This activity reviews the pathophysiology of liver disease and its effects on hepatic drug clearance, along with current approaches to assessing hepatic function, including the Child-Pugh classification, MELD score and emerging noninvasive techniques. Emphasis is placed on how hepatic impairment contributes to variability in drug exposure and informs dose selection, with application to clinical pharmacology and medications used in patients with liver dysfunction. This activity is designed to enhance knowledge of hepatic function assessment, interpretation of pharmacokinetic changes and application of evidence-informed dosing strategies to optimize patient outcomes

Target Audience:

Interprofessional team of Physicians, Pharmacists, PhDs and other health care professionals involved in clinical pharmacology and the care of patients with hepatic impairment.

Learning Objectives

After completing this activity, the learner will be able to:

Registration and Pricing

The American College of Clinical Pharmacology^® (ACCP) offers a monthly article from the The Journal of Clinical Pharmacology (JCP) for continuing education credit. See the CE Info tab for more information on credits. The ACCP JCP Journal CE articles are priced and packaged for January through December of the same calendar year. Packages are available at no cost to ACCP Members and $75/calendar year to Non-members. Once registered, learners have access to all of the Journal CE articles for the calendar year as the articles are released.

To register, log into your ACCP online profile and then register by clicking the green Register button at the top right. Follow the online prompts to complete the registration process and to receive your registration confirmation. If you do not have an ACCP profile, one must be created before you can register for the Journal CE articles. If you do not know if you have a profile, please contact INFO@ACCP1.org for further information to avoid creating duplicate profiles. Please address all other questions to CE@ACCP1.org.

Requirements for Credits

All requirements for claiming CE credits are listed in the CE Info (Handout) tab. Continuing education credits and certificates must be claimed within 30-days of completing the monthly article offering. Continuing Pharmacy Education (CPE) data is uploaded into the CPE Monitor at the end of each month. The pharmacist's NABP# and MMDD of birth must be updated in their ACCP Profile or emailed to CE@ACCP1.org in order to have CPE credits uploaded to the CPE Monitor.

CE Expiration 12/31/2029

2026 ACCP STEP & ESP Webinar: Exposure-Response Analysis Across the Drug Development Continuum: Case Examples from Industry & Regulatory Perspective

Live Session: Wednesday, March 18^th, 2026, from 1:00 to 2:00 PM ET

On Demand: March 18^th, 2026 to March 18^th, 2029

Target audience:

Interprofessional team of MDs, PharmDs, PhDs and other healthcare professionals who are interested in Exposure-Response (E-R) analysis and practical strategies that can be applied within regulatory, industry, and academic settings.

Objectives

After completing this activity, the learner will be able to:  

• Identify common challenges and key considerations for implementing E-R analyses in drug development programs;
• Interpret E-R data to inform dosing strategies and support drug development decision-making;
• Discuss the regulatory expectations on implementation of E-R analyses in regulatory reviews;

Description:

This webinar addresses advanced Exposure-Response (E-R) analysis strategies to support industrial drug development and evaluate regulatory expectations through real-world case examples. Learners who complete this activity will enhance their knowledge of advanced E-R analysis, interpreting regulatory expectations and integrating case-based best practices.

2026 ACCP STEP & ESP Webinar: Exposure-Response Analysis Across the Drug Development Continuum: Foundational Principles

Live Session: Wednesday, March 11^th, 2026, from 1:00 to 2:00 PM ET

On Demand: March 11^th, 2026 to March 11^th, 2029

Target audience:

Interprofessional team of MDs, PharmDs, PhDs and other healthcare professionals who are interested in the foundational E-R principles and practical strategies that can be applied within regulatory, industry, and academic settings.

Objectives

After completing this activity, the learner will be able to:  

• Identify decisions to support, model influence, model risk and model impact;
• Discuss key considerations when creating a qualification plan for Exposure Response (E-R) analyses;
• Identify practical steps to guide the development of credible E-R models.

Description:

This webinar addresses gaps in foundational training on core Exposure–Response (E-R) principles relevant to drug development and clinical pharmacology practice. The presentation will explore practical steps to develop credible, fit-for-purpose E-R models aligned with best practices across the drug development continuum. Learners who complete this activity will enhance their knowledge of foundational E-R concepts, strengthening problem solving and critical thinking skills that can be directly applied to clinical pharmacology and regulatory decision-making settings.

2026 ACCP Peer Review: How to Do it to Maintain Quality & Credibility 

Live Session: Wednesday, February 11^th, 2026, from 1:00 to 2:30 PM ET

On Demand: Wednesday, February 11^th, 2026

Target audience:

Clinical pharmacology professionals, including MDs, PharmDs and PhDs or other professionals with little or no experience in performing peer reviews who are interested in learning more about the process.

Description:

This webinar will examine the role of peer review as a cornerstone of scientific integrity and high-quality biomedical literature. While scientists routinely have their own work peer-reviewed during training and throughout their careers, many have limited exposure to serving as peer reviewers themselves and may not fully understand the process. Join Drs. Joan Korth-Bradley and Mike Fossler as they demystify the peer review process, clarify reviewer expectations and encourage participation in this essential professional responsibility within clinical pharmacology.

Essentials of Planning ACCP Continuing Education Activities - On Demand

Why is this webinar important to your practice? 

This program provides an overview of ACCP requirements and best practices for planning high-quality continuing education (CE) activities that meet accreditation standards for integrity, independence, and educational effectiveness. Participants will review the Standards for Integrity and Independence, including eligibility criteria for organizations, identification and management of relevant financial relationships, and ACCP’s conflict of interest disclosure processes.

The activity also addresses foundational elements of CE design, including selection of appropriate activity types, development of measurable learning objectives aligned with Bloom’s Taxonomy, and integration of active learning strategies. Participants will explore principles of effective assessment design, with an emphasis on distinguishing knowledge-based versus application-based assessments, providing meaningful learner feedback, and avoiding common pitfalls in question writing.

Upon completion, learners will have a clearer understanding of how to develop compliant, learner-centered CE activities that align educational content, instructional methods, and assessment strategies to support independent, evidence-based clinical pharmacology education.

Target Audience:

This activity is designed for ACCP committee members, staff and volunteers who are involved in the planning, development or review of ACCP continuing education activities, including those responsible for completing CE planning documentation, developing learning objectives and supporting compliant assessment design.

Learning Objectives

After completing this activity, the learner will be able to:

• Describe ACCP requirements for planning independent continuing education activities, including criteria for eligible and ineligible organizations.
• Apply ACCP guidelines to develop measurable learning objectives that align with the selected CE activity type and accreditation expectations.
• Demonstrate competence in selecting appropriate assessment methods and writing compliant assessment questions that align with stated learning objectives.

Registration and Pricing

The American College of Clinical Pharmacology^® (ACCP) offers a monthly article from the The Journal of Clinical Pharmacology (JCP) for continuing education credit. See the CE Info tab for more information on credits. The ACCP JCP Journal CE articles are priced and packaged for January through December of the same calendar year. Packages are available at no cost to ACCP Members and $75/calendar year to Non-members. Once registered, learners have access to all of the Journal CE articles for the calendar year as the articles are released.

To register, log into your ACCP online profile and then register by clicking the green Register button at the top right. Follow the online prompts to complete the registration process and to receive your registration confirmation. If you do not have an ACCP profile, one must be created before you can register for the Journal CE articles. If you do not know if you have a profile, please contact INFO@ACCP1.org for further information to avoid creating duplicate profiles. Please address all other questions to CE@ACCP1.org.

Requirements for Credits

All requirements for claiming CE credits are listed in the CE Info (Handout) tab. Continuing education credits and certificates must be claimed within 30-days of completing the monthly article offering. Continuing Pharmacy Education (CPE) data is uploaded into the CPE Monitor at the end of each month. The pharmacist's NABP# and MMDD of birth must be updated in their ACCP Profile or emailed to CE@ACCP1.org in order to have CPE credits uploaded to the CPE Monitor.

CE Expiration 12/31/2028

2025 ACCP Virtual Journal Club Webinar: Examining the Impact of Diet-and-Exercise-Induced Weight Loss on Drug Metabolism and Gastric Emptying in Patients with Obesity - On Demand

Live Session: Thursday, October 9^th, 2025, from 12:00 to 1:00 PM ET

On Demand: October 9^th, 2025 to October 9^th, 2028

Why is this webinar important to your practice? 

This webinar will increase learner knowledge of the effects of diet-and-exercise-induced weight loss on drug-metabolizing enzymes and gastric emptying in patients with obesity. The program will cover drug metabolizing enzymes are affected by diet-and-exercise-induced weight loss in patients with obesity. Learners that complete this webinar will recognize patients with obesity can have lower CYP1A2, CYP2C19, and CYP3A4 activity that counterintuitively implies the need for lower doses of drugs metabolized by these pathways.

Target Audience:

Interprofessional team of Physicians, Pharmacists, PhDs and other healthcare professionals interested in the impact of diet & exercise-induced weight loss on patients with obesity.

Learning Objectives

After completing this activity, the learner will be able to:

1. List at least one cytochrome (CYP) enzyme whereby activity increased after weight loss;
2. Define the parameter used to assess gastric emptying time;
3. Identify at least one single time point metabolic ratio that correlated with exposure (AUC) ratio. 

2025 ACCP STEP & ESP Webinar: Navigating PK Bridging: Essential Strategies for Streamlining Change in Route of Administration in Drug Development

Live Session: Wednesday, June 25^th, 2025, from 1:00 to 2:30 PM ET

On Demand: June 25^th, 2025 to June 25^th, 2028

Target audience:

Interprofessional team of MDs, PharmDs, PhDs and other healthcare professionals across the spectrum of academia, industry, regulatory and clinical settings who are interested in the use of PK bridging strategies in therapeutic drug monitoring.

Objectives

After completing this activity, the learner will be able to:  

• Recognize the importance and need for PK bridging during therapeutic development;
• Identify key scenarios requiring PK bridging strategies between IV and SC formulations drug drug development;
• Discuss the challenges and opportunities for model-informed PK bridging strategies;
• Describe the multidisciplinary perspectives on PK bridging in practice.

Description:

This webinar will explore how pharmacokinetic (PK) bridging is a cornerstone of successful formulation changes, with a specific focus on intravenous (IV) to subcutaneous (SC) transitions. Industry and regulatory experts will examine how the PK landscape has evolved and share practical, forward-looking strategies—including model-informed drug development approaches—to address the complexities of bridging. Real-world case studies will provide insight into what has worked, what hasn’t and why. Whether you're in early development or managing a late-stage formulation shift, this session will equip you with the scientific, regulatory and strategic knowledge needed to implement effective PK bridging and streamline development. Attendees will gain a clear understanding of when PK bridging is essential, how to recognize key decision points and what tools and cross-functional perspectives are shaping the future of route transition in drug development. Learners who complete this activity will have enhanced knowledge in the use of PK bridging strategies in therapeutic drug monitoring.